Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion

0
115
AI firm ​Profluent said ‌on Tuesday ​it ​has struck a ⁠multi-program ​research ​collaboration with U.S. drugmaker ​Eli ​Lilly worth up ‌to $2.25 ⁠billion to develop ​AI-designed ​enzymes ⁠for genetic ​medicines.

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here